Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Community engagement in health promotion campaigns: A qualitative photo content analysis from vitalizing communities against NCD risk factors (V-CaN) field trial in rural central India.
Samanthapudi AV, Wanjari D, Sharma R, Rajashekhar M, Kalantri A, Raut AV, Gupta SS. Samanthapudi AV, et al. Among authors: kalantri a. J Educ Health Promot. 2024 Aug 29;13:328. doi: 10.4103/jehp.jehp_202_24. eCollection 2024. J Educ Health Promot. 2024. PMID: 39429818 Free PMC article.
Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in India: A Phase 2-3 Randomized Clinical Trial.
Gunale B, Kapse D, Kar S, Bavdekar A, Kohli S, Lalwani S, Meshram S, Raut A, Kulkarni P, Samuel C, Munshi R, Gupta M, Plested JS, Cloney-Clark S, Zhu M, Pryor M, Hamilton S, Thakar M, Shete A, Dharmadhikari A, Bhamare C, Shaligram U, Poonawalla CS, Mallory RM, Glenn GM, Kulkarni PS; COVOVAX-Ped study group. Gunale B, et al. JAMA Pediatr. 2023 Jul 31;177(9):911-20. doi: 10.1001/jamapediatrics.2023.2552. Online ahead of print. JAMA Pediatr. 2023. PMID: 37523166 Free PMC article.
Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study.
Kulkarni PS, Kadam A, Godbole S, Bhatt V, Raut A, Kohli S, Tripathi S, Kulkarni P, Ludam R, Prabhu M, Bavdekar A, Gogtay NJ, Meshram S, Kadhiravan T, Kar S, Narayana DHA, Samuel C, Kulkarni G, Gaidhane A, Sathyapalan D, Raut S, Hadda V, Bhalla HL, Bhamare C, Dharmadhikari A, Plested JS, Cloney-Clarke S, Zhu M, Pryor M, Hamilton S, Thakar M, Shete A, Gautam M, Gupta N, Panda S, Shaligram U, Poonawalla CS, Bhargava B, Gunale B, Kapse D; COVOVAX Study Group. Kulkarni PS, et al. Lancet Reg Health Southeast Asia. 2023 Mar;10:100139. doi: 10.1016/j.lansea.2022.100139. Epub 2023 Jan 11. Lancet Reg Health Southeast Asia. 2023. PMID: 36647543 Free PMC article.
Vitalizing Community for Health Promotion Against Modifiable Risk Factors of Noncommunicable Diseases (V-CaN) in Rural Central India: Protocol for a Hybrid Type II Implementation Effectiveness Trial.
Mundra A, Kalantri A, Jakasania A, Sathe H, Raut A, Maliye C, Bahulekar P, Dawale A, Paradkar RJ, Siriah S, Kumar S, Gupta SS, Garg B. Mundra A, et al. Among authors: kalantri a. JMIR Res Protoc. 2023 Sep 29;12:e42450. doi: 10.2196/42450. JMIR Res Protoc. 2023. PMID: 37773622 Free PMC article.
24 results